Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
According to a small multi-center, phase II trial reported in NEJM, an investigational targeted drug for some patients with metastatic thyroid cancer can induce partial responses. References and…
The tumor-derived vaccine vitespen (Oncophage) does not prevent renal-cell carcinoma recurrence or improve survival despite promising early results. References and Resources Wood C, Srivastava P, Bukowski R, et…
Nancy A. Kernan, MD, Assistant Chief, Pediatric Bone Marrow Service, Director, Unrelated Donor Program, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the importance of SuperSibs!, a national…
At the American Society of Clinical Oncology meeting, data from a small retrospective analysis suggest that diabetic patients with breast cancer had significantly higher rates of response to…
Douglas S. Hawkins, MD, Associate Professor, Pediatrics, Children’s Hospital and regional Medical Center, Seattle WA, discusses pharmacogenomics of chemotherapy. For more information on this physician visit: SeattleChildrens.org .
As presented at ASCO, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28% response rate and an overall survival edge for refractory glioblastoma. Also presented at…
Mary Wright, MD, Associate Professor & Director, Breast Center, Section of Breast Surgery, Department of Surgery, Tulane University School of Medicine, discusses Tulane’s Breast Cancer Center. References and…
A meta-analysis of observational studies showed that oral estrogen, but not transdermal estrogen, increased the risk of venous thromboembolism. References and Resources Canonico M, Plu-Bureau G, Lowe GD,…
Using a multivariate regression analysis, it has been shown that people with a common genetic mutation have up to twice the risk of lung cancer as do people…
Vivek K. Mehta, MD, Radiation Oncologist, Director, Center for Advanced Targeted Radiotherapies, Department of Radiation Oncology, Swedish Cancer Institute, Seattle, WA, discusses volumetric arc therapy. References and Resources…
